Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 2/3 3Phase 1/2 2

Status

Unknown 4Active not recruiting 4Terminated 3Completed 3Recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Gynecologic 1Gastrointestinal 1CNS 1

Conditions

Liver Neoplasms 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Carcinoma, Ovarian Epithelial 1Brain Neoplasms 1

Interventions

Cisplatin 270Oxaliplatin 195Carboplatin 191Capecitabine 184Docetaxel 178apatinib 164Paclitaxel 163Bevacizumab 159Gemcitabine 156Radiotherapy 147camrelizumab 146Fluorouracil 144Cyclophosphamide 126Irinotecan 120Drug Therapy 120sintilimab 108Etoposide 99anlotinib 90S 1 (combination) 89pembrolizumab 86Leucovorin 86toripalimab 78Pemetrexed 78Doxorubicin 77tislelizumab 76Dexamethasone 71Trastuzumab 65Neoadjuvant Therapy 65Rituximab 62Cetuximab 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Unknown × Tyrosine Kinase Inhibitors × Clear all
NCT06059885 2023-09-29

Tislelizumab Plus TKI as Adjuvant Therapy Versus Active Surveillance in Patients With HCC

Beijing 302 Hospital

Phase 2 Unknown
60 enrolled
Gastrointestinal

Liver Neoplasms

NCT05422183 2022-06-16

Envafolimab, Lenvatinib Combined With VP-16 in Platinum-resistant Recurrent Epithelial Ovarian Cancer

Zhongda Hospital

Phase 2 Unknown
20 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial

NCT04760431 2021-06-02

TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2 Unknown
120 enrolled
CNS

Brain Neoplasms

NCT02687425 2016-02-22

SESPI

Tongji Hospital

Phase 2 Unknown
20 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡